{
  "abstract": "Objectives Methods Single-center retrospective case series (Istanbul University-Cerrahpasa; Jan 2019-Aug 2025) of 7 SLE patients (2019 EULAR/ACR) refractory to standard care and RTX, treated with OBZ (1,000 mg IV on Days 1 and 15, then every 6 months; steroid premedication) with stable background therapy. Ethics-approved with consent; de-identified data. Standardized, verified extraction of demographics, phenotype, prior therapies, and labs (anti-dsDNA, C3/C4, 24-hour proteinuria). SLEDAI-2K assessed at baseline, 6, and 12 months; primary outcome: 12-month SLEDAI-2K change; secondary: serologies/proteinuria and safety (adverse events, infections, hypogammaglobulinemia). Descriptive analyses.Results The study included seven SLE patients receiving OBZ, of whom two were male; the median age was 28 years. Organ involvement included lupus nephritis in 5/7 (Class III n=1, Class V n=2, Class III/V n=2), SLE enteritis in 1/7, and treatment-resistant inflammatory arthritis in 1/7. The indication to switch from RTX was non-response in 4/7 and infusion/hypersensitivity intolerance in 4/7. OBZ exposure was a median of 3 courses (range 2-4), with background immunosuppression maintained per protocol. Among nephritis cases, 2/5 achieved clinical remission at 12 months, 1/5 achieved partial remission, and 2/5 were non-responders (Cases 1 and 7), according to predefined criteria; both the enteritis and arthritis cases achieved sustained clinical remission on OBZ. No serious adverse events or infections were observed. One patient had pre-existing hypogammaglobulinemia attributed to prior RTX; no new-onset hypogammaglobulinemia occurred during OBZ treatment.Abstract PO:12:322 Table 1Clinical and laboratory feature of seven cases of systemic lupus erythematosus who were non-responsive to RTX-RTX intoleranceConclusions In this small real-world cohort of RTX-refractory/intolerant SLE, OBZ yielded promising responses, including in lupus nephritis, with acceptable safety. These findings support OBZ as a therapeutic option in difficult-to-treat SLE; larger prospective studies are needed to confirm efficacy, optimize sequencing, and define long-term safety.",
  "authors": [
    {
      "affiliations": [
        "Istanbul University-Cerrahpasa Medical Faculty, Istanbul, Turkey"
      ],
      "name": "Esra Firat Senturk"
    },
    {
      "affiliations": [
        "Istanbul University-Cerrahpasa Medical Faculty, Istanbul, Turkey",
        "Systemic lupus erythematosus (SLE) can be challenging to manage in treatment-resistant cases, for which rituximab (RTX) is commonly recommended. In patients who are refractory to or intolerant of RTX, obinutuzumab (OBZ), a next-generation type II anti-CD20 monoclonal antibody, may represent an alternative therapeutic option. Although the NOBILITY and REGENCY trials demonstrated the efficacy of OBZ in proliferative lupus nephritis, its role in RTX-resistant or RTX-intolerant SLE remains unclear. We describe seven SLE cases treated with OBZ following RTX non-response or intolerance"
      ],
      "name": "Zeynep Toker Dincer"
    },
    {
      "affiliations": [
        "Istanbul University-Cerrahpasa Medical Faculty, Istanbul, Turkey",
        "Systemic lupus erythematosus (SLE) can be challenging to manage in treatment-resistant cases, for which rituximab (RTX) is commonly recommended. In patients who are refractory to or intolerant of RTX, obinutuzumab (OBZ), a next-generation type II anti-CD20 monoclonal antibody, may represent an alternative therapeutic option. Although the NOBILITY and REGENCY trials demonstrated the efficacy of OBZ in proliferative lupus nephritis, its role in RTX-resistant or RTX-intolerant SLE remains unclear. We describe seven SLE cases treated with OBZ following RTX non-response or intolerance"
      ],
      "name": "Alican Karakoc"
    },
    {
      "affiliations": [
        "Istanbul University-Cerrahpasa Medical Faculty, Istanbul, Turkey",
        "Systemic lupus erythematosus (SLE) can be challenging to manage in treatment-resistant cases, for which rituximab (RTX) is commonly recommended. In patients who are refractory to or intolerant of RTX, obinutuzumab (OBZ), a next-generation type II anti-CD20 monoclonal antibody, may represent an alternative therapeutic option. Although the NOBILITY and REGENCY trials demonstrated the efficacy of OBZ in proliferative lupus nephritis, its role in RTX-resistant or RTX-intolerant SLE remains unclear. We describe seven SLE cases treated with OBZ following RTX non-response or intolerance"
      ],
      "name": "Serdal Ugurlu"
    }
  ],
  "title": "PO:12:322 Obinutuzumab experience in systemic lupus erythematosus patients: case series",
  "uid": "94ba82e1-d17d-59a4-bce6-3413c8e782f0"
}